Antiretrovirals
Abacavir/3TC co-formulation available in expanded access
The once-daily coformulation of abacavir/3TC from GlaxoSmithKline is also progressing through the regulatory pipeline. Although expanded-access programmes are driven by medical urgency for a new compound prior to marketing approval, a programme is now available in the UK for patients who are in such a situation.
Doctors interested in accessing abacavir/3TC in this formulation should contact Jan Williams (named-patient administrator) on 020 8990 2317 or GSK Medical Information on 0800 085 8747.
Source: GSK expanded access programme
Links to external websites are current at time of posting but not maintained.